TCTN1 and glioblastoma: We compared the survival of all GBM patients with TCTN1 expression above or below the median expression and found a statistically significant disadvantage in overall survival for patients with higher TCTN1 expression (Log-rank P =0.006; Cox regression HR =1.32, 95% CI 1.08-1.61; Figure 3A).